ADVOCATE Trial Now Enrolling

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics for autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.

PARTICIPATE IN RESEARCH:  ChemoCentryx has an ongoing Phase 3 clinical research study in ANCA-associated vasculitis (AAV) that is currently enrolling patients with AAV at various study locations across the United States. The study is called ADVOCATE.  Click here to learn more.


NOW ENROLLING PATIENTS:  The purpose of the ADVOCATE Trial is to learn if avacopan (previously called CCX168) can provide benefits to patients by being safe and effective in improving vasculitis disease activity, kidney function, and/or quality of life.  Avacopan is being studied for ANCA vasculitis.  For people who suffer from vasculitis who may want to participate in the ADVOCATE Trial, more information can be found on the ADVOCATE website.

Dr. Peter Merkel, principal investigator for the ADVOCATE Trial, explains the science behind Avacopan and the role of neutrophils in ANCA vasculitis.
Breakdown of Webinar:
The science behind ADVOCATE:  2:52
Neutrophils and their role:  4:01
What is avacopan?  5:36
Rational for use of avacopan:  6:48
ADVOCATE and clinical trials:  9:38
ADVOCATE Trial – Study design specifics:  26:18
ADVOCATE Trial – Study schedule:  27:29
Inclusion criteria – How do you get into the trial? 32:04
Summary:  34:36TO LEARN MORE ABOUT THE ADVOCATE TRIAL:  Click here to learn more.